Chamutal Gur

A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states

Mor Zada, Anna Kurilovich, Noam Shapira, Shuang-Yin Wang et autres

il (code pays fourni par la source)

Localized PD-1 CAR T therapy reprograms neuroinflammation

Rotem Shalita, Maya Ben Yehuda, Chamutal Gur, Yasmin Frid et autres

il, de, ch (code pays fourni par la source)

Synovium-Restricted Armored PD-1-Targeted CAR-T Cells Reprogram Immunity and Resolve Experimental Arthritis

Chamutal Gur, Lior Ravkaie, Reut Sharet-Eshed, Rotem Shalita et autres

Abstract Despite major therapeutic advances, a substantial fraction of patients with autoimmune disease remains refractory to treatment. While B cell-targeted CAR-T therapies have shown considerable efficacy, the central contribution of pathogenic T cells to rheumatoid arthritis (RA) suggests that complementary T cell-directed …

il (code pays fourni par la source)

B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis

Shlomit Kfir‐Erenfeld, Shlomo Elias, Nathalie Asherie, Hadass Pri Chen et autres

OBJECTIVE: To evaluate the safety and preliminary efficacy of HBI0101, B cell maturation antigen targeted chimeric antigen receptor T cell therapy, in patients with severe refractory systemic lupus erythematosus or systemic sclerosis. METHODS: We conducted an ongoing phase 1 trial of HBI0101 …

il (code pays fourni par la source)

Targeting Bladder Cancer with Inactivated Uropathogenic E. coli: A Novel Alternative to BCG Immunotherapy

Vladimir Yutkin, Naseem Maalouf, Chamutal Gur, A Zini et autres

More than 90% of bladder cancers are classified as urothelial carcinomas (UC), with approximately 75% of these cases presenting as non-muscle-invasive bladder cancer (NMIBC). Bacillus Calmette–Guérin (BCG) is the current standard immunotherapy for NMIBC, yet it suffers from limited efficacy, frequent tumor …

il, ru, us (code pays fourni par la source)

Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy

Michelle von Locquenghien, Pascale Zwicky, Ken Xie, Diego Adhemar Jaitin et autres

il, us (code pays fourni par la source)

BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial

Shlomo Elias, Hadass Pri Chen, Shlomit Kfir‐Erenfeld, Nathalie Asherie et autres

Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy offers a promising, targeted approach for treating severe, refractory autoimmune diseases by eliminating autoreactive immune cells. By engineering autologous T cells to recognize disease-specific antigens, this strategy has the potential to induce durable remission …

il (code pays fourni par la source)

B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Refractory Autoimmune Diseases

Hadass Pri Chen, Chamutal Gur, Shlomo Elias, Polina Stepensky

Background: B cells are key drivers of autoimmune diseases, however current B-cell–targeted therapies rarely induce lasting remission. Chimeric antigen receptor (CAR) T-cell therapy is now being explored for autoimmune diseases, and CD19-targeted CAR T cells have shown efficacy in refractory cases. Yet, …

il (code pays fourni par la source)

Dissection of the immune landscape in psoriatic arthritis defines immunoproteasome up-regulation in treatment resistance

Reut Tzemach, Chamutal Gur, Truong San Phan, Eyal David et autres

Despite substantial advancements in psoriatic arthritis (PsA) treatment modalities, a considerable proportion of patients continue to experience persistent joint inflammation, unresponsive to the armamentarium of disease-modifying antirheumatic drugs. Identifying previously unknown biomarkers and targets for refractory disease is urgently needed. Here, using …

il (code pays fourni par la source)

ZEB2 is a master switch controlling the tumor-associated macrophage program

Fadi Sheban, Truong San Phan, Ken Xie, Florian Ingelfinger et autres

il, us, cn (code pays fourni par la source)

Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols

Oren Barboy, Akhiad Bercovich, Hanjie Li, Yaniv Eyal-Lubling et autres

il, cn, gb, us (code pays fourni par la source)

Supplementary Figure S6 from Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary

Ido Yofe, Tamar Shami, Noam Cohen, Tomer Landsberger et autres

The metastatic core and invasive margin are populated by distinct macrophage subpopulations.